Related Experiment Video
Updated: Jun 24, 2026
07:09
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
Glycemic index, glycemic load, and thrombogenesis
Jennie Brand-Miller1, Scott Dickinson, Alan Barclay
1Institute of Obesity, Nutrition and Exercise, and Department of Medicine, University of Sydney and Royal Prince Alfred Hospital, Camperdown, NSW, Australia. j.brandmiller@mmb.usyd.edu.au
Seminars in Thrombosis and Hemostasis
|March 25, 2009
Summary
High blood sugar and insulin resistance increase cardiovascular disease (CVD) risk. Choosing low glycemic index (GI) and glycemic load (GL) foods can help manage blood sugar spikes and improve heart health outcomes.
Area of Science:
- Nutrition Science
- Cardiovascular Health
- Metabolic Disorders
Background:
- Hyperglycemia and insulin resistance are established independent risk factors for cardiovascular disease (CVD).
- Postprandial glycemic excursions negatively impact vascular health through mechanisms like oxidative stress, inflammation, and protein glycation.
- Dietary carbohydrate quantity and quality significantly influence glycemic responses.
Purpose of the Study:
- To evaluate the role of dietary glycemic index (GI) and glycemic load (GL) in predicting and managing cardiovascular disease risk.
- To assess the impact of low-GI carbohydrate diets on CVD risk factors in overweight individuals.
Main Methods:
- Analysis of prospective observational studies correlating dietary GI and GL with CVD incidence.
- Review of randomized controlled trials (RCTs) investigating the effects of low-GI diets on CVD risk markers in overweight populations.
Main Results:
- Prospective studies show dietary GI and GL independently predict CVD risk, with higher intakes associated with increased relative risk.
- RCTs demonstrate that low-GI carbohydrate diets reduce plasminogen activator inhibitor-1 activity and other CVD risk factors beyond conventional low-fat diets.
- Glycemic responses are reliably predicted by considering both carbohydrate quantity and quality (GI).
Conclusions:
- Dietary glycemic index and glycemic load are significant independent predictors of cardiovascular disease.
- Low-GI/GL diets offer a therapeutic strategy to mitigate CVD risk factors, particularly in overweight individuals.
- Clinicians can leverage low-GI/GL food recommendations to potentially improve patient cardiovascular outcomes.
Related Concept Videos
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...